

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

EDITORIAL

- Vancomycin-Resistant Bacteria 193
DAVID M. SHLAES, MD, PHD

ORIGINAL ARTICLES

- A Cluster of Vancomycin-Resistant *Enterococcus faecium* in an Intensive Care Unit 195

LYNNE V. KARANFIL, RN, MA, CIC; MARY MURPHY, MD;
ADELE JOSEPHSON, PHD, MPH, CIC; ROBERT GAYNES, MD; LAURA MANDEL, MD;
BERTHA C. HILL; JANA M. SWENSON, MMSc

- Risk Factors for Epidemic *Xanthomonas maltophilia* Infection/Colonization in Intensive Care Unit Patients 201

MARGARITA E. VILLARINO, MD, MPH; LANE E. STEVENS, BS; BARBARA SCHABLE, BS;
WENDOLYN MAYERS, DVM; J. MICHAEL MILLER, PHD; JOHN P. BURKE, MD;
WILLIAM R. JARVIS, MD

- Determinants of Clean Surgical Wound Infections for Breast Procedures at an Oncology Center 207

COLEMAN ROTSTEIN, MD; RICHARD FERGUSON, MD; K. MICHAEL CUMMINGS, PHD,
PH; MARION R. PIEDMONTE, MA; JOYCE LUCEY, RN, MS; ANNE BANISH, RN, BSN

- Impact of Central Venous Catheter Removal on the Recurrence of Catheter-Related Coagulase-Negative Staphylococcal Bacteremia 215

ISSAM RAAD, MD; STEVE DAVIS, MD; ASMA KHAN, MD; JEFFREY TARRAND, MD;
LINDA ELTING, PHD; GERALD P. BODEY, MD

SPECIAL COMMENTARY

- Interpersonal Communication: A Review of Eye Contact 222
RUTH DAVIDHIZAR, RN, DNS, CS

BEYOND INFECTION CONTROL: THE NEW HOSPITAL EPIDEMIOLOGY

- The Application of Continuous Quality Improvement to Healthcare 226
MICHAEL D. DECKER, MD, MPH

LETTERS TO THE EDITOR

- Body Substance Isolation (and Reply) 191

INGE GUREVICH, RN, MA
MARGUERITE M. JACKSON, RN, MS, CIC; PATRICIA LYNCH, RN, MBA, CIC

- SHEA NEWS 231

Introducing the benefits of catheter-related

ARROWgard™*. The first and only blue line of central venous catheters.

Complications due to catheter-related bacteremia are medically unacceptable when the causes are preventable. And in today's health-care climate, the monetary cost of treating nosocomial infection versus the cost of prevention is similarly unacceptable.

Fortunately, the forces of prevention have gained a new weapon, ARROWgard™ is a patented colonization-

resistant chlorhexidine and silversulfadiazine antiseptic surface molecularly bonded into the polyurethane catheter material along the entire indwelling length of each ARROWgard™ blue line CVC.

A recent study indicates that catheters with ARROWgard™ protection were twofold less likely to be colonized than control catheters and *fourfold less likely to produce bacteremia*. The study also noted a considerable lengthening of the safe indwelling period for ARROWgard™ catheters compared to control catheters.¹

ARROWgard™ infection protection is presently available in select multi-lumen** and single-lumen CVC kits. It will soon be available on other Arrow critical-care products.

The benefits of CVCs are not without risk.

There is no question that central venous catheterization (CVC) represents

a significant medical advancement, particularly in treatment of the critically ill. However, with increased usage there is an increased risk of CVC-related infection.

The reported frequency of intravascular device-associated bacteremia is between 0.2% and 0.5% for IV peripheral catheters, up to 7.0% for central parenteral nutrition catheters and from 3.8% to 12.0% for central venous catheters.² In short, 80% to 90% of each year's cases of intravascular-related bloodstream infection arise from the use of CVCs.³ Moreover, a 10% to 20% case Fatality rate has been associated with catheter-related bacteremia.³

In an address to

the Third International Conference on Nosocomial Infections, Dr. Dennis Maki stated that *one-third of nosocomial infections are preventable, especially the 50,000 cases a year that develop from CVCs*. Some 80% of these catheter-related infections arise from bacteria found on the skin that migrate down the catheter track, Dr. Maki noted.

Awareness is, of course, part of the battle. But more ammunition is needed. And that's why we developed ARROWgard™.

More infection control means more financial control.


In a study published in 1988

reporting 1986 results, Hampton and Sheretz determined that nosocomial infection added a mean of seven days to a normal hospital stay and *increased the cost by a mean of more than \$6,000!*⁵ An additional downside: Medicare reimburses very little of the cost if a hospital stay is extended to treat bacteremia.

When you add the increases in cost since these studies were made, the economic impact of CVC-related infection is even more severe. And while new drugs to fight septic infections offer hope of better management in some crisis cases, the extreme costs pose a clinical dilemma for caregivers.

But ARROWgard™ can help reverse those spiraling figures.

Let's say that a hospital places 500 multi-lumen CVCs a year. If the infection rate is 4%, 20 infections result. By




**4% Infection Rate and \$6,000 Mean Cost.^{5,6} bringing the infection rate down to 2%*

1. Maki, DG, Archer, G, Archer, G, Archer, G, Archer, G, Archer, G. A comparison of chlorhexidine-coated central venous catheter. Abstract of paper presented at 31st ICAAC Clinical Infections Conference, 1990. 2. Archer, G, Archer, G, Archer, G, Archer, G, Archer, G, Archer, G. Catheter-related infections related to central venous catheters. Surg Infect. 1990; 1: 65-72. 3. Archer, G, Archer, G. Catheter-related infections related to central venous catheters. Surg Infect. 1990; 1: 65-72. 4. Maki, DG. Catheter-related infections related to central venous catheters. Surg Infect. 1990; 1: 65-72. 5. Hampton, AD, Sheretz, RJ. Nosocomial infections in hospitalized patients. Crit Care Med. 1988; 16: 71-75. 6. Hampton, AD, Sheretz, RJ. Nosocomial infections in hospitalized patients. Crit Care Med. 1988; 16: 71-75.

ginning of the end ed bacteremia.

venous catheters with built-in infection protection.

10 cases would be avoided-and, at the figure of \$6,000 per case for added hospitalization, the added cost for infection would be cut in half, from \$120,000 to \$60,000. At a cost of \$57.75 per ARROWgard™ multi-lumen CVC kit, or \$28,875 for 500 multi-lumen CVCs, you can see that the hospital saves \$31,125. You retain over half the savings



even after subtracting the catheter cost. Even more important than the economics, potentially, lives may be saved.² Further, you must consider the unnecessary expenditure of time and energy on the part of your staff and the trauma and suffering of the patient.

Additional patient and physician benefits.

Select Arrow multi-lumen and single-lumen central venous catheters now carry ARROWgard™ protection. And there are other impressive benefits built into select ARROWgard™ CVC kits and sets. These features add up to better patient care with every use.

- The Arrow Blue FlexTip® is an integral catheter tip which is more pliant than the body. It remains patent yet

deflects in case of inadvertent contact with the vessel walls to reduce perforation risk.

- Flexible thromboresistant polyurethane material softens in situ for excellent indwelling characteristics.
- The Arrow® Raulerson Introducer Syringe***

has a hollow plunger/balloon containing a patented valving system. It allows a spring-wire guide to be placed directly into the vessel lumen so there's less trauma, less contamination risk, and virtually no chance for air embolism.

- The Arrow Advancer™ saves you time by helping you to easily straighten the "J"-tip spring-wire guide and insert it with one hand, advancing it to the proper position with your thumb.
- A centimeter-marked spring-wire

guide (.025" and .035" diameters available) aids in accurate and positive catheter placement.

MEDIAL 18GA

DISTAL 16G

PROXIMAL 14

Not only does Arrow offer more benefits, but you have a wider choice of kits, sets, and accessories for central venous catheterization from Arrow than from any other source.

Ask for our free infection-control information packet

We have prepared a helpful packet on infection control. It contains many of the articles referenced in this brochure and CVC informational literature. For your free packet, call your Arrow representative, or contact us directly by calling 1 800 233-3187, Ext. 3294, and ask for Joanne.

Refer to package insert for current warnings, precautions, and instructions for use.

*ARROWgard™ is a joint development of Daltex Medical Sciences, Inc., and Arrow International, Inc., using technology developed by Dr. Shanta Modak and her colleagues, in the Department of Surgery, Columbia University. U.S. Patent Numbers 4,612,337, 4,563,485, 4,581,028, 5,019,096 apply. Other U.S. and foreign patents pending.

**U.S. Patent Number RE-31879. Canadian Patent Number 1,112,533. Foreign patents pending and issued. The Arrow-Howes™ Multi-Lumen Central Venous Catheter is a joint development of Randolph Howes, M.D., Ph.D., and Arrow International, Inc.

***U.S. Patent Number 4,831,936. Other U.S. and foreign patents pending. The Arrow® Raulerson Syringe is a joint development of J. Daniel Raulerson, M.D., and Arrow International, Inc.

ARROW
INTERNATIONAL, INC.

Contact our Customer Relations Department for further information: 3000 Bernville Road, Reading, PA 19605, U.S.A. Distribution worldwide; offices in Canada, Germany, Japan, and The Netherlands.

Due to product availability, catheters initially may be manufactured in a color other than blue.

DO YOU REALLY KNOW WHAT YOU'RE GETTING INTO?

If you work in a high-risk medical area, you know the hazards. So does Ansell. That's why we've introduced our new E.P.[™] Gloves. They provide the extra protection you need because E.P. Gloves are manufactured and tested to even tighter requirements than the current industry standards for surgical gloves. They also provide features for added protection not available with other gloves in the marketplace today.

Ansell E.P. Gloves Provide Extra Protection By:

- Testing to ten times tighter **AQL** than the industry standard for surgical gloves*
- **100%** electronic inspection for pinholes
- No powder added
- **Thicker** latex
- Long, 12" cuff
- Textured wet-grip surface
- Meeting industry guidelines for handling cytotoxic drugs**
- Availability in four sizes, **petite**, small, medium, and **large**

So get your hands into Ansell's new E.P. Gloves — before your get into anything else. For more information and a FREE pair of E.P. Gloves, call today.

*American Society for the Testing of Materials (ASTM) D3577-78a

**Occupational Safety & Health Administration (OSHA) Instruction PUB 8-1.1 "Work Practice Guidelines for Personnel Dealing with Cytotoxic (Antineoplastic) Drugs" January 29, 1986

Ansell Medical

Ansell Incorporated
P.O. Box 1252, Dothan, Alabama 36302
800-327-8659 205-794-4231 (in Alabama)

© 1990 Ansell Incorporated All Rights Reserved



INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

CONTENTS

EDITORIAL

Vancomycin-Resistant Bacteria 193

DAVID M. SHLAES, MD, PHD

ORIGINAL ARTICLES

A Cluster of Vancomycin-Resistant *Enterococcus faecium* in an Intensive Care Unit 195

LYNNE V. KARANFIL, RN, MA, CIC; MARY MURPHY, MD;
ADELE JOSEPHSON, PHD, MPH, CIC; ROBERT GAYNES, MD; LAURA MANDEL, MD;
BERTHA C. HILL; JANA M. SWENSON, MMSc

Risk Factors for Epidemic *Xanthomonas maltophilia* Infection/Colonization in
Intensive Care Unit Patients 201

MARGARITA E. VILLARINO, MD, MPH; LANE E. STEVENS, BS;
BARBARA SCHABLE, BS; GWENDOLYN MAYERS, DVM; J. MICHAEL MILLER, PHD;
JOHN P. BURKE, MD; WILLIAM R. JARVIS, MD

Determinants of Clean Surgical Wound Infections for Breast Procedures at an Oncology Center 207

COLEMAN ROTSTEIN, MD; RICHARD FERGUSON, MD; K. MICHAEL
CUMMINGS, PhD, MPH; MARION R. PIEDMONTE, MA, JOYCE LUCEY, RN, MS;
ANNE BANISH, RN, BSN

Impact of Central Venous Catheter Removal on the Recurrence of Catheter-Related
Coagulase-Negative Staphylococcal Bacteremia 215

ISSAM RAAD, MD; Steve DAVIS, MD; ASMA KHAN, MD; JEFFREY TARRAND, MD;
LINDA ELTING, PHD; GERALD P. BODEY, MD

SPECIAL COMMENTARY

Interpersonal Communication: A Review of Eye Contact 222

RUTH DAVIDHIZAR, RN, DNS, CS

**BEYOND INFECTION CONTROL:
THE NEW HOSPITAL EPIDEMIOLOGY**

The Application of Continuous Quality Improvement to Healthcare 226

MICHAEL D. DECKER, MD, MPH

DEPARTMENTS

Information for Authors 188

Letters to the Editor 191

SHEA News 231

Medical News 233

Media Reviews 237

Calendar of Events 240

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HOSPITAL EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

PUBLISHER: Infection Control and Hospital Epidemiology (ISSN-0899-823X) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (609) 8481000.

COPYRIGHT 1992 by The Society for Hospital Epidemiology of America, Inc. and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

SUBSCRIPTIONS: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year—\$80.00; Two years—\$115.00; Three years—\$145.00; Institutional: One year—\$90.00; Two years—\$130.00; Three years—\$170.00. Fellows: \$40 per year. Canada: \$18.00 additional each year; all other countries: \$36.00 additional each year. Single copies of current issues may be obtained for \$15.00. United States and possessions: \$20.00 all other countries.

REPRINTS: All requests to reprint or use material published herein should be addressed to Lester J. Robeson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Lester T. Robeson at (609) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

CHANGE OF ADDRESS: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086, and additional entry points. **POSTMASTER:** Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents—Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, and Laboratory Performance Information Exchange System.

EDITORIAL OFFICES

Vanderbilt University School of Medicine
 A-1131 Medical Center North
 Nashville, TN 37232-2637
 (615) 343-1095; (615) 343-1882 (FAX)
 Email: iche@mcmail.vanderbilt.edu

EDITOR

Michael D. Decker, MD, MPH

MANAGING EDITOR

Susan Cantrell

STATISTICAL EDITOR

Beverly G. Mellen, PhD

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

SECTION EDITORS**Beyond Infection Control:****The New Hospital Epidemiology**

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

Information Management

John A. Sellick, DO

Buffalo, New York

The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

SHEA News

Murray D. Batt, MD

Clarksburg, West Virginia

Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

EDITORIAL ADVISORY BOARD

- Jacques F. Acar, MD Paris, France
 J. Wesley Alexander, MD Cincinnati, Ohio
 Paul Arnow, MD Chicago, Illinois
 Graham A.J. Ayliffe, MD Birmingham, United Kingdom
 Neil L. Barg, MD Yakima, Washington
 Elizabeth Ann Bolyard, RN, MPH, CIC Atlanta, Georgia
 John M. Boyce, MD Providence, Rhode Island
 Professor Dr. Ilja Braveny Munich, Federal Republic of Germany
 Charles Bryan, MD Columbia, South Carolina
 Christian Brun-Buisson, MD Creteil, France
 Donald E. Craven, MD Boston, Massachusetts
 Sue Crow, MSN, RN, CIC Shreveport, Louisiana
 Franz Daschner, MD Freiburg, Federal Republic of Germany
 Leigh G. Donowitz, MD Charlottesville, Virginia
 Charles E. Edmiston, Jr., PhD Milwaukee, Wisconsin
 Theodore C. Eickhoff, MD Denver, Colorado
 Bruce Farber, MD Manhasset, New York
 Victoria J. Fraser, MD St. Louis, Missouri
 Peter C. Fuchs, MD, PhD Black Butte, Oregon
 Richard A. Garibaldi, MD Farmington, Connecticut
 Velvl Greene, PhD, MPH Beer Sheva, Israel
 Robert Gaynes, MD Atlanta, Georgia
 David W. Gregory, MD Nashville, Tennessee
 David K. Henderson, MD Bethesda, Maryland
 Peter N.R. Heseltine, MD Los Angeles, California
 Karen Hoffmann, RN, CIC, MS Chapel Hill, North Carolina
 Marguerite McMillan Jackson, RN, PhD San Diego, California
 Janine Jagger, MPH, PhD Charlottesville, Virginia
 William R. Jarvis, MD Atlanta, Georgia
 Douglas S. Kernodle, MD Nashville, Tennessee
 Robert H. Latham, MD Nashville, Tennessee
 Lewis B. Lefkowitz, MD Nashville, Tennessee
 Hsieh-Shong Leu, MD, MSc Taipei, Taiwan
 Jack Levy, MD Brussels, Belgium
 Victor Lorian, MD Bronx, New York
 Dennis G. Maki, MD Madison, Wisconsin
 Professor Dr. Walter Marget Munich, Federal Republic of Germany
 William J. Martone, MD Bethesda, Maryland
 Allison McGeer, MD Toronto, Ontario, Canada
 John E. McGowan, Jr., MD Atlanta, Georgia
 Jonathan L. Meakins, MD, DSc Montreal, Quebec, Canada
 Raf Mertens, MD Brussels, Belgium
 Robert R. Muder, MD Pittsburgh, Pennsylvania
 Joseph M. Mylotte, MD, CIC Buffalo, New York
 Lindsay Nicolle, MD Winnipeg, Manitoba, Canada
 Juhani Ojajarvi, MD Helsinki, Finland
 Michael T. Osterholm, PhD, MPH Minneapolis, Minnesota
 Jan Evans Patterson, MD San Antonio, Texas
 Sindy M. Paul, MD Trenton, New Jersey
 Michael A. Pfaller, MD Iowa City, Iowa
 Samuel Ponce de Leon, MD, MSc Mexico City, Mexico
 Isaam Raad, MD Houston, Texas
 Manfred L. Rotter, MD, DipBact Vienna, Austria
 Theodore Sacks, MD Jerusalem, Israel
 William E. Scheckler, MD Madison, Wisconsin
 Kent Sepkowitz, MD New York City, New York
 Denis Spelman, MD Prahran Victoria, Australia
 Michael L. Tapper, MD New York, New York
 Clyde Thornsberry, PhD Brentwood, Tennessee
 Professor Leonid P. Titov Minsk, Republic of Belarus
 Timothy R. Townsend, MD Millwood, Virginia
 Antoni Trilla, MD, PhD Barcelona, Spain
 Professor Wang Shu-Qun Beijing, People's Republic of China
 J. John Weems, Jr., MD Greenville, South Carolina
 Robert A. Weinstein, MD Chicago, Illinois
 Professor Dr. W. Weuffen Greifswald, Federal Republic of Germany
 Sergio B. Wey, MD São Paulo, Brazil
 Rebecca Wurtz, MD Evanston, Illinois

SLACK Incorporated

6900 Grove Road
 Thorofare, New Jersey 08086
 (609) 848-1000

Vice President/Group Publisher

Richard N. Roash

Publisher

John C. Carter

Editorial Director

Jennifer Kilpatrick

Production Editor

Shirley P. Strunk, ELS

Assistant Editor

Eileen C. Anderer

Circulation Manager

Lester J. Robeson, CCCP

Production Director

Christine Malin

Production Coordinator

Joanne Patterson

Publishing Director/ Advertising

Wayne McCourt

Pharmaceutical Group Sales Director

Michael LoPresti

Advertising Sales Representative



Jennine Kane

Classified/Recruitment Sales Manager

Michele Burch

It's fluid repellent.
It's loaded with
extra protection.
It's very
breathable. It's
comfortable,
and it's what
you've asked for!

UNIQUE
FOUR-
LAYER
CONSTRUCTION



Now, get the added protection you need
with the comfort you demand, in the
BARRIER[®] Extra Protection Face Mask
from Johnson & Johnson Medical, Inc.
To try one on, contact your Johnson &
Johnson Medical sales representative
or call 1-800-433-5009.



Johnson & Johnson
MEDICAL INC.

TRADEMARK © JMI, INC. 1992

Twenty-eight years ago
we declared germ warfare.

Cidex*

And today we're still winning the battle.

Johnson & Johnson Medical, Inc. revolutionized the science of disinfection with the introduction of CIDEX* Activated Dialdehyde Solution twenty-eight years ago. While other products have come and gone, CIDEX Solution is still here, with a total system of products to satisfy your disinfecting needs.

The original CIDEX Solution has grown to include a full line of CIDEX Solutions, CIDEX* Solution Test Strips and ENZOL* Enzymatic

Detergent. All have been specially formulated to perform to the high standards of efficacy that you demand.

Depend on Johnson & Johnson Medical to lead the charge in asepsis and infection control. For additional information on the complete family of disinfecting products, call 1-800-433-5009, or contact your Johnson & Johnson Medical sales representative.



Johnson & Johnson
MEDICAL INC.

*TRADEMARK © JJM, INC 1992